United States Patent 8,231,885: Scope of Claims, Claim Construction Levers, and U.S. Landscape
What is the claim core and where does infringement risk sit?
U.S. Patent 8,231,885 centers on a topical dermal formulation that combines three compulsory elements:
- Therapeutically effective brimonidine (or a pharmaceutically acceptable salt)
- Titanium dioxide
- A pharmaceutically acceptable carrier for skin application, where the carrier type is selected from a defined list (sprays, mists, aerosols, lotions, gels, creams, pastes, emulsions, and in narrower dependent claim sets, ointments/unguents)
The independent claim is effectively broad on formulation vehicle while narrow on what the vehicle must be used for (topical skin application) and on where the product is applied (in specific claims, limited to facial and non-ophthalmic use). The claims also add formulation constraints through dependent claims tied to pH, quantitative brimonidine concentration (0.01 to 5 wt%), and optional ingredients like preservatives, local anesthetics, and skin humectants.
What do the independent claims actually cover?
Claims 1, 17, 18, and 20 (and related dependent claims) define the main coverage contours.
Claim 1 (composition; broadest framing)
A topical dermal composition comprising:
- brimonidine or pharmaceutically acceptable salt
- titanium dioxide
- carrier selected from: sprays, mists, aerosols, lotions, gels, creams, pastes, emulsions
- composition is suitable for application to skin
In practice: this is not a method-of-treatment claim. It reads on any topical skin product that contains all three components in the claimed relationship. It also avoids specifying a concentration for brimonidine in the independent claim, leaving that to dependent claims.
Claim 17 (composition; broader carrier list)
Same three compulsory elements, but carrier list includes additional vehicle types:
- sprays, mists, aerosols, lotions, gels, creams, ointments, unguents, pastes, emulsions
Also uses “active agent consisting of” language for the active agent, which locks the “active agent” concept to brimonidine (or salt) rather than permitting other actives under that “active agent consisting of” umbrella.
Claim 18 (container for delivering the formulation)
A container suitable for delivering a topical formulation comprising:
- brimonidine (or salt)
- titanium dioxide
- carrier selected from the same list as claim 1
This expands enforceability into packaging/delivery systems where the container is tied to the presence of the claimed formulation.
Claim 20 (composition; use limitation)
Adds an explicit use scope:
- limited to facial and non-ophthalmic topical application
This matters for design-around. If an accused product is intended for, or marketed as, ocular/periocular use (even if applied to face), this claim’s explicit limitation can become a key factual and claim-construction battleground.
Which dependent claims materially narrow the scope?
Dependent claims 2 through 16 (and 19, 21, 22) impose additional technical constraints that can either (a) define fallback positions in enforcement, or (b) create design-around opportunities if competitors satisfy only the independent claim and not the dependent claim features.
pH limitation
- Claim 2: pH about 5 to 8
- Claim 5: pH about 5 to 8 (in the aqueous gel context)
This is a formulation parameter. For infringement, pH is measured at a defined point, and the accused product must align with the claimed “about” range.
Carrier narrowed to aqueous gel
- Claim 3: carrier is an aqueous gel
Then further:
- Claim 4: brimonidine present at about 0.01 to 5 wt%
- Claim 5: pH about 5 to 8
- Claim 9: aqueous gel comprises:
- water
- and a “water-gelling amount” of gelling agent selected from:
- carbomers
- glycerine polyacrylate
- mixtures thereof
The gelling agent selection becomes a very specific technical lever for product formulation and potential non-infringement if the competitor uses different gelling agents or non-gelled carriers.
Optional formulation additives
In the aqueous gel (claim 6–8 context), and similarly in cream (claims 13–15):
- Claim 6 / 13: further comprising a preservative
- Claim 7 / 14: further comprising a local anesthetic
- Claim 8 / 15: further comprising a skin humectant
These are “further comprising” additions; they do not exclude other components unless the claim language “consisting of” is used for specific sub-features. For the core composition, these are optional and typically do not prevent infringement if present or absent unless the dependent claim is asserted as a narrower claim.
Cream-specific constraints
- Claim 10: carrier is a cream
- Claim 11: brimonidine at about 0.01 to 5 wt%
- Claim 12: pH about 5 to 8
- Claim 16: cream comprises:
- stearic acid
- stearyl alcohol
- cetyl alcohol
- glycerin
- water
This last dependent claim is a recipe-level constraint. A competitor using a different cream base may avoid claim 16 while still potentially falling within claim 10 or claim 1 depending on overall carrier characterization.
Container scope and product form factor
- Claim 19: carrier is a gel or cream and container is a squeeze bottle or tube
This is a narrow device-delivery constraint.
Face and non-ophthalmic limitation again
- Claims 20 and 21: composition limited to facial and non-ophthalmic topical application
- Claim 21: uses “active agent consisting of” brimonidine (or salt) again, alongside titanium dioxide and the carrier list.
Container with face/non-ophthalmic limitation
- Claim 22: container delivering a formulation limited to facial and non-ophthalmic topical application
What is the practical claim construction “surface area” competitors must navigate?
The claims are structurally designed so that a large formulation portion is covered by independent claim language, with dependent claims creating narrower fallback territory.
Below is a map of the main infringement determinants.
| Claim element |
Where it is required |
Competitive design lever |
| Brimonidine (or salt) |
All cited claims |
Substitute different active, or remove brimonidine entirely |
| “Therapeutically effective amount” |
All composition claims |
Dose testing can matter, but independent claims do not specify a numeric band |
| Titanium dioxide |
All cited claims |
Avoid TiO2 or replace with non-titanium UV/opacity excipients |
| Carrier type list |
Claim 1 and 17/18/20/21/22 |
Use a vehicle arguably not within the list (but “carrier selected from” can be construed broadly to commonly categorized vehicles) |
| pH 5–8 |
Claims 2 and 5, 12 |
Adjust pH out of range (consider “about”) |
| Aqueous gel |
Claims 3, 4, 5, 6, 7, 8, 9 |
Use different carrier class than aqueous gel (or different gelling agents) |
| Gelling agents carbomer / glycerine polyacrylate |
Claim 9 |
Switch to different polymer/gelling system |
| Brimonidine wt% 0.01–5 |
Claims 4, 11 |
Set concentration outside the band (dose claims depend on assay and “about”) |
| Cream base ingredients |
Claim 16 |
Reformulate cream base away from specified ingredients |
| Facial + non-ophthalmic use |
Claims 20, 21, 22 |
Product positioning, labeling, and intended use matter |
| Squeeze bottle or tube |
Claim 19 (container claim) |
Change delivery container type |
Where are the strongest enforcement hooks?
- TiO2 + brimonidine topical skin products: independent claims are straightforward. Any product containing both brimonidine and titanium dioxide within the listed carriers is squarely within the claim structure.
- Face, non-ophthalmic use positioning: claims 20–22 provide a stronger factual narrative for targeted products marketed for facial use that explicitly exclude ocular use.
- Gel/cream specific fallback: dependent claims (aqueous gel and cream, with pH and brimonidine wt% ranges) provide additional predicates if a general “carrier characterization” argument fails.
How does “consisting of” vs “comprising” alter scope?
Two distinct drafting approaches appear:
- “comprising” appears in the independent composition claims 1 and 20, meaning additional components are allowed in the composition.
- “active agent consisting of” appears in claims 17, 21, and 21’s related language, meaning that the “active agent” portion is limited to brimonidine (or salt). This can matter if a competitor argues the product includes another active ingredient that might otherwise be treated as part of the “active agent” category.
In practical enforcement, “consisting of” can be a litigation hinge if an accused product includes additional actives and the dispute turns on whether those actives fall under the claimed “active agent” concept.
Patent landscape: what can be concluded from the claim text provided?
The prompt includes only the claim set; it does not supply the underlying patent bibliographic data (assignee, filing date, priority claims), cited references, prosecution history, or related patents. Without that, a defensible U.S. landscape analysis cannot be completed.
Given the constraint, the only accurate landscape statements that can be made from the text you provided are claim-set-driven:
- The patent is directed to topical brimonidine formulations that include titanium dioxide.
- It includes vehicle-type breadth (multiple topical carrier classes) but narrows with dependent claims into specific pH, brimonidine concentration band, and specific gelling agent systems and cream base ingredients, plus a facial/non-ophthalmic use limitation in several claims.
- A generic competitor can design around by targeting either the titanium dioxide requirement or the active ingredient requirement (brimonidine), as those are central mandatory elements.
Because no citation set, family members, prosecution citations, or competitor patents are provided, no additional U.S. patent mapping (overlap by assignee, competing formulations, enforcement activity, or expiry timelines) can be produced without risking factual fabrication.
Key Takeaways
- Core infringement trigger: a topical skin product that contains both brimonidine (or salt) and titanium dioxide in a listed carrier type.
- Primary narrowing levers: pH 5–8, brimonidine 0.01–5 wt%, aqueous gel with carbomer or glycerine polyacrylate, cream base composition, and facial/non-ophthalmic use.
- Design-around pathways that directly attack compulsory elements: remove titanium dioxide or remove/replace brimonidine.
- “Active agent consisting of” claims create additional room for disputes if an accused formulation includes other actives that could be argued as part of the “active agent” portion.
FAQs
-
Does the independent claim require a specific brimonidine concentration?
No. Independent claim 1 (and similarly structured independents) does not state a numeric brimonidine % band; that appears in dependent claims (0.01 to 5 wt%).
-
Is titanium dioxide mandatory in every claim shown?
Yes. Every cited claim set you provided includes titanium dioxide as a required component.
-
Can the product include other ingredients besides brimonidine and titanium dioxide?
Yes. The main structure uses “comprising,” which allows additional ingredients. The “consisting of” language limits the “active agent” concept in specific claims.
-
What claims include a pH range?
Claims 2, 5, and 12 specify pH about 5 to 8.
-
What does the facial and non-ophthalmic limitation change?
Claims 20–22 require that the composition is limited to facial and non-ophthalmic topical application, which can affect both product labeling/intent and infringement arguments.
